Nicole Paulk

Nicole Paulk is a researcher at the University of California San Francisco (UCSF), focusing on advancing adeno-associated virus (AAV) gene therapies for rare genetic diseases and cancer. She leads the Paulk Lab, which develops technologies to improve AAV delivery, efficacy, and safety while reducing costs. Her affiliations include the UCSF Neurologic Oncology, Helen Diller Family Comprehensive Cancer Center, Glioblastoma Precision Medicine Program, and Liver Center.

• PhD in Viral Gene Therapy from Oregon Health & Science University (2012)
• Postdoctoral training in Human Gene Therapy at Stanford University (2016)
• BS in Medical Microbiology from Central Washington University (2006)

Dr. Paulk's research centers on overcoming barriers in AAV gene therapy, including vector production, immunogenicity, and organ-specific delivery. Her work emphasizes liver diseases and glioblastoma, with recent studies exploring proteomic characterization of AAV vectors and high-dose AAV applications.

Her publications highlight innovations in AAV vector engineering, proteomic analysis, and gene targeting strategies. Key grants include NIH/NIBIB U01-EB029374, NIH K01DK107607, and support from the American Society of Gene & Cell Therapy.

• NIH/NIBIB U01-EB029374 (2018-2023)
• UCSF CATALYST PROGRAM Award (2020-2021)
• NIH K01DK107607 (2016-2021)
• AMERICAN SOCIETY OF GENE & CELL THERAPY Grant (2018-2019)

Dr. Paulk's lab investigates scalable solutions for AAV-based therapies, including methods for vector validation and tumor barcoding. Her interdisciplinary approach bridges virology, biotechnology, and clinical medicine to address unmet needs in genetic and oncologic conditions.